medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2008, Number 3

<< Back Next >>

Ann Hepatol 2008; 7 (3)

PTEN at the crossroad of metabolic diseases and cancer in the liver

Vinciguerra M, Foti M

Language: Spanish
References: 123
Page: 192-199
PDF size: 317.12 Kb.


Text Extraction

The tumor suppressor PTEN is a phosphoinositide phosphatase regulating the PI3K/Akt signaling pathways and mutated or deleted in a variety of human cancers. Recent evidence indicates that dysregulated PTEN expression and activity in the liver critically affect hepatic insulin sensitivity and trigger the development of non-alcoholic fatty liver diseases. As well, PTEN expression/activity is also affected with HBV and HCV infection, or following alcohol-related injury. Finally, PTEN mutations/deletions or low PTEN expression are associated with diverse liver malignancies thus suggesting a critical role for PTEN in hepatic cancers. This review will focus on our current knowledge of the regulation of PTEN expression/activity and the role of this phosphatase in liver diseases.


REFERENCES

  1. Shepherd PR. Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues. Acta Physiol Scand 2005; 183: 3-12.

  2. Hawkins PT, et al. Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 2006; 34: 647-62.

  3. Downes CP, et al. Substrate specificity and acute regulation of the tumour suppressor phosphatase, PTEN. Biochem Soc Symp 2007: 69-80.

  4. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954-63.

  5. Steck PA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356-62.

  6. Li J, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-7.

  7. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-90.

  8. Vinciguerra M, Foti M. PTEN and SHIP2 phosphoinositide phosphatases as negative regulators of insulin signalling. Arch Physiol Biochem 2006; 112: 89-104.

  9. Stiles B, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A 2004; 101: 2082-7.

  10. Horie Y, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004; 113: 1774-83.

  11. Butler M, et al. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 2002; 51: 1028-34.

  12. Xu J, et al. Decreased hepatic futile cycling compensates for increased glucose disposal in the Pten heterodeficient mouse. Diabetes 2006; 55: 3372-80.

  13. Wong JT, et al. Pten (phosphatase and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity. Diabetologia 2007; 50: 395-403.

  14. Kurlawalla-Martinez C, et al. Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol Cell Biol 2005; 25: 2498-510.

  15. Wijesekara N, et al. Muscle-specific Pten deletion protects against insulin resistance and diabetes. Mol Cell Biol 2005; 25: 1135-45.

  16. Vinciguerra M, et al. PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. Gastroenterology 2008; 134: 268-80.

  17. Lo YT, et al. Increase of PTEN gene expression in insulin resistance. Horm Metab Res 2004; 36: 662-6.

  18. Mocanu MM, Field DC, Yellon DM. A Potential Role for PTEN in the Diabetic Heart. Cardiovasc Drugs Ther 2006; 20: 319-21.

  19. Lackey J, et al. Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling. Oncogene 2007; 26: 7132-42.

  20. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005; 22: 1129-33.

  21. Contos MJ, et al. The histologic spectrum of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 481-500, vii.

  22. Choudhury J, Sanyal AJ. Insulin resistance in NASH. Front Biosci 2005; 10: 1520-33.

  23. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99.

  24. Watanabe S, Horie Y, Suzuki A. Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma. Hepatol Res 2005; 33: 161-6.

  25. Sato W, et al. Hepatic gene expression in hepatocyte-specific Pten deficient mice showing steatohepatitis without ethanol challenge. Hepatol Res 2006; 34: 256-65.

  26. Vereshchagina N, Wilson C. Cytoplasmic activated protein kinase Akt regulates lipid-droplet accumulation in Drosophila nurse cells. Development 2006; 133: 4731-5.

  27. Dong X, et al. Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J Clin Invest 2006; 116: 101-14.

  28. Taniguchi CM, Ueki K, Kahn R. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 2005; 115: 718-27.

  29. Simpson L, et al. PTEN expression causes feedback upregulation of insulin receptor substrate 2. Mol Cell Biol 2001; 21: 3947-58.

  30. Kuwano K. PTEN as a new agent in the fight against fibrogenesis. Am J Respir Crit Care Med 2006; 173: 5-6.

  31. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006; 25: 3787-800.

  32. Zhang L, et al. Study of the PTEN gene expression and FAK phosphorylation in human hepatocarcinoma tissues and cell lines. Mol Cell Biochem 2004; 262: 25-33.

  33. Xu X, et al. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 2006; 116: 1843-52.

  34. Furumoto Y, et al. Cutting Edge: Lentiviral short hairpin RNA silencing of PTEN in human mast cells reveals constitutive signals that promote cytokine secretion and cell survival. J Immunol 2006; 176: 5167-71.

  35. Kwak YG, et al. Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J Clin Invest 2003; 111: 1083-92.

  36. Lee KS, et al. PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. Faseb J 2005; 19: 1033-5.

  37. Parish R, Petersen KF. Mitochondrial dysfunction and type 2 diabetes. Curr Diab Rep 2005; 5: 177-83.

  38. Begriche K, et al. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28.

  39. Sanyal AJ, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.

  40. Caldwell SH, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 430-4.

  41. Pagliarini DJ, Worby CA, Dixon JE. A PTEN-like phosphatase with a novel substrate specificity. J Biol Chem 2004; 279: 38590-6.

  42. Zhu Y, et al. PTEN: a crucial mediator of mitochondria-dependent apoptosis. Apoptosis 2006; 11: 197-207.

  43. Stambolic V, et al. Regulation of PTEN transcription by p53. Mol Cell 2001; 8: 317-25.

  44. Yahagi N, et al. p53 involvement in the pathogenesis of fatty liver disease. J Biol Chem 2004; 279: 20571-5.

  45. Matoba S, et al. p53 regulates mitochondrial respiration. Science 2006; 312: 1650-3.

  46. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004; 127: S87-96.

  47. Nagata K, Suzuki H, Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci 2007; 32: 453-68.

  48. Sastre J, et al. Mitochondrial function in liver disease. Front Biosci 2007; 12: 1200-9.

  49. Minuk GY, et al. The effect of long-term, voluntary ethanol consumption on hepatic regeneration in rats. Can J Physiol Pharmacol 1991; 69: 341-5.

  50. Gong Y, Cui L, Minuk GY. Effects of acute and chronic ethanol exposure on the hepatic gamma-aminobutyric acid transport system in rats. Alcohol 1999; 19: 213-8.

  51. Apte UM, McRee R, Ramaiah SK. Hepatocyte proliferation is the possible mechanism for the transient decrease in liver injury during steatosis stage of alcoholic liver disease. Toxicol Pathol 2004; 32: 567-76.

  52. Lopez-Valencia V, et al. Involvement of alcohol and aldehyde dehydrogenase activities on hepatic retinoid metabolism and its possible participation in the progression of rat liver regeneration. Biochem Pharmacol 2007; 73: 586-96.

  53. Yeon JE, et al. Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. Hepatology 2003; 38: 703-14.

  54. Yao XH, Nyomba BL. Hepatic insulin resistance induced by prenatal alcohol exposure is associated with reduced PTEN and TRB3 acetylation in adult rat offspring. Am J Physiol Regul Integr Comp Physiol 2008; 294: R1797-806.

  55. Shulga N, Hoek JB, Pastorino JG. Elevated PTEN levels account for the increased sensitivity of ethanol-exposed cells to tumor necrosis factor-induced cytotoxicity. J Biol Chem 2005; 280: 9416-24.

  56. He J, de la Monte S, Wands JR. Acute ethanol exposure inhibits insulin signaling in the liver. Hepatology 2007; 46: 1791-800.

  57. Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol 2005; 3: 27.

  58. Tan A, et al. Viral hepatocarcinogenesis: from infection to cancer. Liver Int 2008; 28: 175-88.

  59. Negro F. Insulin resistance and HCV: Will new knowledge modify clinical management? J Hepatol 2006; 45: 514-9.

  60. Wang CC, et al. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol 2008; 23: 779-82.

  61. Chung TW, et al. Hepatitis B Virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res 2003; 63: 3453-8.

  62. Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. Faseb J 2004; 18: 1123-5.

  63. Kang-Park S, et al. PTEN modulates hepatitis B virus-X protein induced survival signaling in Chang liver cells. Virus Res 2006; 122: 53-60.

  64. Kang-Park S, Lee YI, Lee YI. PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells. FEBS Lett 2003; 545: 203-8.

  65. Waris G, et al. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol 2007; 81: 8122-30.

  66. Rahman MA, et al. Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: possible relationship with COX II and inducible nitric oxide synthase. Int J Cancer 2002; 100: 152-7.

  67. Parkin DM, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.

  68. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-87.

  69. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008; 133: 403-14.

  70. Yao YJ, et al. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 1999; 18: 3181-5.

  71. Wu SK, et al. Expression of PTEN, PPM1A and P-Smad2 in hepatocellular carcinomas and adjacent liver tissues. World J Gastroenterol 2007; 13: 4554-9.

  72. Dong-Dong L, Xi-Ran Z, Xiang-Rong C. Expression and significance of new tumor suppressor gene PTEN in primary liver cancer. J Cell Mol Med 2003; 7: 67-71.

  73. Cotler SJ, et al. Immunohistochemical expression of components of the Akt-mTORC1 pathway is associated with hepatocellular carcinoma in patients with chronic liver disease. Dig Dis Sci 2008; 53: 844-9.

  74. Hu TH, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003; 97: 1929-40.

  75. Wan XW, et al. The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma. J Cancer Res Clin Oncol 2003; 129: 100-6.

  76. Podsypanina K, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 1999; 96: 1563-8.

  77. Zucman-Rossi J, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006; 43: 515-24.

  78. Bioulac-Sage P, et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol 2007; 46: 521-7.

  79. Paradis V, et al. Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology 2007; 46: 140-6.

  80. Tate G, Suzuki T, Mitsuya T. Mutation of the PTEN gene in a human hepatic angiosarcoma. Cancer Genet Cytogenet 2007; 178: 160-2.

  81. Cervello M, Montalto G. Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol 2006; 12: 5113-21.

  82. Honjo S, et al. COX-2 inhibitor, NS398, enhances Fas-mediated apoptosis via modulation of the PTEN-Akt pathway in human gastric carcinoma cell lines. DNA Cell Biol 2005; 24: 141-7.

  83. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-46.

  84. Hwang PH, et al. PTEN/MMAC1 enhances the growth inhibition by anticancer drugs with downregulation of IGF-II expression in gastric cancer cells. Exp Mol Med 2005; 37: 391-8.

  85. Perks CM, et al. IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 2007; 26: 5966-72.

  86. Wang H, et al. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res 2007; 67: 2922-6.

  87. Leslie NR, et al. PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol 2007; 17: 115-25.

  88. Shen WH, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128: 157-70.

  89. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006; 25: 3778-86.

  90. Lee TK, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 2006; 12: 5369-76.

  91. Tamura M, et al. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280: 1614-7.

  92. Itoh S, et al. Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res 2004; 10: 2812-7.

  93. Kotelevets L, et al. The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. J Cell Biol 2001; 155: 1129-35.

  94. Kotelevets L, et al. Implication of the MAGI-1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness. Faseb J 2005; 19: 115-7.

  95. Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007; 45: 1298-305.

  96. Okumura K, et al. PCAF modulates PTEN activity. J Biol Chem 2006; 281: 26562-8.

  97. Gericke A, Munson M, Ross AH. Regulation of the PTEN phosphatase. Gene 2006; 374: 1-9.

  98. Leslie NR. The redox regulation of PI 3-kinase-dependent signaling. Antioxid Redox Signal 2006; 8: 1765-74.

  99. Trotman LC, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007; 128: 141-56.

  100. Vasudevan KM, Gurumurthy S, Rangnekar VM. Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 2004; 24: 1007-21.

  101. Zhang W, et al. PPARgamma Activator Rosiglitazone Inhibits Cell Migration via Upregulation of PTEN in Human Hepatocarcinoma Cell Line BEL-7404. Cancer Biol Ther 2006; 5.

  102. Whelan JT, Forbes SL, Bertrand FE. CBF-1 (RBP-J kappa) binds to the PTEN promoter and regulates PTEN gene expression. Cell Cycle 2007; 6: 80-4.

  103. Hettinger K, et al. c-Jun promotes cellular survival by suppression of PTEN. Cell Death Differ 2007; 14: 218-29.

  104. Virolle T, et al. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 2001; 3: 1124-8.

  105. Palomero T, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007; 13: 1203-10.

  106. Shen YH, et al. Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling. A cross-talk between stress signaling and insulin signaling in resistin-treated human endothelial cells. J Biol Chem 2006; 281: 7727-36.

  107. Kim RH, Mak TW. Tumours and tremors: how PTEN regulation underlies both. Br J Cancer 2006; 94: 620-4.

  108. Pan L, et al. Histone deacetylase inhibitor trichostatin a potentiates doxorubicin-induced apoptosis by up-regulating PTEN expression. Cancer 2007; 109: 1676-88.

  109. Schagdarsurengin U, et al. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003; 22: 1866-71.

  110. Wang L, et al. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res 2007; 37: 389-396.

  111. Mehnert JM, Kelly WK. Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 2007; 13: 23-9.

  112. Meng F, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-58.

  113. Pezzolesi MG, et al. Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am J Hum Genet 2008; 82: 1141-9.

  114. Xiao C, Srinivasan L, Calado DP, Patterson HC, Zhang B, Wang J, Henderson JM, Kutok JL, Rajewsky K. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 2008; 9: 405-14.

  115. Yang H, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-33.

  116. Schmid AC, et al. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett 2004; 566: 35-8.

  117. Nigorikawa K, et al. A naphthoquinone derivative, shikonin, has insulin-like actions by inhibiting both phosphatase and tensin homolog deleted on chromosome 10 and tyrosine phosphatases. Mol Pharmacol 2006; 70: 1143-9.

  118. Rosivatz E, et al. A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol 2006; 1: 780-90.

  119. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007; 13: 433-42.

  120. Cortes Sempere M, et al. The role of the NFkappaB signalling pathway in cancer. Clin Transl Oncol 2008; 10: 143-7.

  121. Calzado M, et al. NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr Med Chem 2007; 14: 367-76.

  122. Mack GS. MicroRNA gets down to business. Nat Biotechnol 2007; 25: 631-8.

  123. Stenvang J, Kauppinen S. MicroRNAs as targets for antisense-based therapeutics. Expert Opin Biol Ther 2008; 8: 59-81.




2020     |     www.medigraphic.com